📊 PRME Key Takeaways
Is Prime Medicine, Inc. (PRME) a Good Investment?
Prime Medicine faces critical financial distress with $167.1M annual free cash flow burn against only $63M cash on hand, resulting in approximately 4-5 months of runway at current burn rate. While revenue shows promising 55.3% YoY growth and loss metrics are improving, the company remains pre-commercial stage with $4.6M in revenue against $208.3M operating losses, making near-term dilutive financing or clinical success essential for survival.
Why Buy Prime Medicine, Inc. Stock? PRME Key Strengths
- Revenue growth of 55.3% YoY demonstrates commercial traction and market demand
- Zero long-term debt and clean balance sheet with $342.7M in total assets
- Improving profitability metrics: EPS improved 18.2% YoY and operating losses appear to be moderating
- Excellent liquidity with 4.84x current ratio provides near-term operational flexibility
PRME Stock Risks: Prime Medicine, Inc. Investment Risks
- Severe cash burn ($167.1M annually) with only $63M cash equivalents creates existential refinancing risk within 4-5 months
- Extreme operating margin of -4498% and net margin of -4342% indicate unsustainable cost structure relative to revenue
- Pre-commercial biotech model: $4.6M revenue against $208.3M operating expenses suggests long development cycle ahead
- Company will require substantial dilutive financing or face insolvency; common in early-stage biotech but indicates high shareholder risk
- Typical biotech risks including clinical trial failures, regulatory rejection, and extended development timelines
Key Metrics to Watch
- Operating cash burn rate and runway months remaining
- Revenue growth trajectory and path toward gross margin expansion
- Clinical trial progress and regulatory milestones for pipeline programs
- Capital raise activity and dilution impact on existing shareholders
- Time to profitability or operating cash flow breakeven
Prime Medicine, Inc. (PRME) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.84x current ratio provides a solid financial cushion.
PRME Profit Margin, ROE & Profitability Analysis
PRME vs Healthcare Sector: How Prime Medicine, Inc. Compares
How Prime Medicine, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Prime Medicine, Inc. Stock Overvalued? PRME Valuation Analysis 2026
Based on fundamental analysis, Prime Medicine, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Prime Medicine, Inc. Balance Sheet: PRME Debt, Cash & Liquidity
PRME Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Prime Medicine, Inc.'s revenue has declined by 11% over the 5-year period, indicating business contraction. The most recent EPS of $-1.65 indicates the company is currently unprofitable.
PRME Revenue Growth, EPS Growth & YoY Performance
PRME Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $209.0K | -$45.8M | $-0.32 |
| Q2 2025 | N/A | -$45.8M | $-0.41 |
| Q1 2025 | $591.0K | -$45.8M | $-0.40 |
| Q3 2024 | N/A | -$39.4M | $-0.44 |
| Q2 2024 | N/A | -$39.4M | $-0.46 |
| Q1 2024 | N/A | -$39.4M | $-0.44 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Prime Medicine, Inc. Dividends, Buybacks & Capital Allocation
PRME SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Prime Medicine, Inc. (CIK: 0001894562)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRME
What is the AI rating for PRME?
Prime Medicine, Inc. (PRME) has an AI rating of STRONG SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRME's key strengths?
Claude: Revenue growth of 55.3% YoY demonstrates commercial traction and market demand. Zero long-term debt and clean balance sheet with $342.7M in total assets.
What are the risks of investing in PRME?
Claude: Severe cash burn ($167.1M annually) with only $63M cash equivalents creates existential refinancing risk within 4-5 months. Extreme operating margin of -4498% and net margin of -4342% indicate unsustainable cost structure relative to revenue.
What is PRME's revenue and growth?
Prime Medicine, Inc. reported revenue of $4.6M.
Does PRME pay dividends?
Prime Medicine, Inc. does not currently pay dividends.
Where can I find PRME SEC filings?
Official SEC filings for Prime Medicine, Inc. (CIK: 0001894562) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRME's EPS?
Prime Medicine, Inc. has a diluted EPS of $-1.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PRME a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Prime Medicine, Inc. has a STRONG SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PRME stock overvalued or undervalued?
Valuation metrics for PRME: ROE of -166.4% (sector avg: 15%), net margin of -4,342.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PRME stock in 2026?
Our dual AI analysis gives Prime Medicine, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRME's free cash flow?
Prime Medicine, Inc.'s operating cash flow is $-162.6M, with capital expenditures of $4.5M. FCF margin is -3,607.4%.
How does PRME compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,342.4% (avg: 12%), ROE -166.4% (avg: 15%), current ratio 4.84 (avg: 2).